Form 4: Immunovant CMO Sells Shares to Cover Tax Obligations

Immunovant's Chief Medical Officer, Michael Geffner, sold 2,385 shares of common stock at $18.15 per share to satisfy tax withholding obligations related to the vesting of restricted stock units.

Summary

• Michael Geffner, Chief Medical Officer of Immunovant, Inc. (IMVT), reported a sale of 2,385 shares of common stock.
• The transaction occurred on July 23, 2025, at a price of $18.15 per share.
• The sale was a 'sell to cover' transaction, mandated by the issuer to satisfy tax withholding obligations arising from the vesting of 6,250 restricted stock units (RSUs).
• These RSUs were part of a larger grant of 100,000 RSUs on January 17, 2023, with the 6,250 units vesting on July 17, 2025.
• Following this transaction, Michael Geffner beneficially owns 221,825 shares of Immunovant common stock.

Sentiment

Score: 5

Explanation: The transaction is a routine 'sell to cover' to satisfy tax obligations upon RSU vesting, indicating a neutral sentiment as it is not a discretionary sale by the insider.

Positives

• The sale was non-discretionary, solely to cover tax withholding obligations, indicating no change in the executive's investment conviction.
• Michael Geffner retains a substantial beneficial ownership of 221,825 shares in Immunovant, Inc.

Negatives

• No discretionary sale by the Chief Medical Officer, therefore no negative implications regarding management's confidence in the company.

Risks

• No specific risks are detailed in this Form 4 filing, as it primarily reports an insider transaction for tax purposes.

Future Outlook

N/A. This Form 4 filing reports a past insider transaction and does not provide forward-looking statements or guidance.

Management Comments

• The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary transaction by the Reporting Person.

Industry Context

N/A. This filing is a routine insider transaction report specific to Immunovant, Inc. and does not provide broader industry context.

Stakeholder Impact

• Shareholders: Minimal impact as it's a non-discretionary sale, not indicative of a change in management's confidence.

Key Dates

Recommendation

The reported transaction is a non-discretionary 'sell to cover' to satisfy tax obligations related to RSU vesting. It does not reflect a change in the Chief Medical Officer's investment conviction or the company's fundamentals, thus a 'hold' recommendation is appropriate as this event does not provide new information to alter an existing investment thesis.

Keywords

Immunovant, IMVT, Michael Geffner, Chief Medical Officer, insider trading, Form 4, stock sale, RSU, restricted stock units, tax withholding, sell to cover